Abionyx Pharma SA (ABNX) - Total Liabilities

Latest as of June 2025: €7.56 Million EUR ≈ $8.84 Million USD

Based on the latest financial reports, Abionyx Pharma SA (ABNX) has total liabilities worth €7.56 Million EUR (≈ $8.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ABNX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Abionyx Pharma SA - Total Liabilities Trend (2013–2024)

This chart illustrates how Abionyx Pharma SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Abionyx Pharma SA balance sheet assets.

Abionyx Pharma SA Competitors by Total Liabilities

The table below lists competitors of Abionyx Pharma SA ranked by their total liabilities.

Company	Country	Total Liabilities
LITHIUM IONIC CORP. F:H3N	Germany	€39.47 Million
Act Co Ltd KQ:138360	Korea	₩43.97 Billion
Yusin Holding Corp TW:4557	Taiwan	NT$2.69 Billion
Bullpen Parlay Acquisition Co NASDAQ:BPAC	USA	$1.64 Million
Sungdo Engineering & Construction Co. Ltd KQ:037350	Korea	₩372.09 Billion
Real Estate & E-Commerce Split Corp TO:RS	Canada	CA$117.81 Million
Lifetime Brands Inc NASDAQ:LCUT	USA	$396.48 Million
Adrad Holdings Ltd AU:AHL	Australia	AU$64.07 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Abionyx Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Abionyx Pharma SA balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.40	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abionyx Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abionyx Pharma SA (2013–2024)

The table below shows the annual total liabilities of Abionyx Pharma SA from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	€6.03 Million ≈ $7.05 Million	-12.82%
2023-12-31	€6.91 Million ≈ $8.08 Million	-20.13%
2022-12-31	€8.65 Million ≈ $10.12 Million	-22.42%
2021-12-31	€11.15 Million ≈ $13.04 Million	+204.86%
2020-12-31	€3.66 Million ≈ $4.28 Million	+2.12%
2019-12-31	€3.58 Million ≈ $4.19 Million	-61.46%
2018-12-31	€9.30 Million ≈ $10.87 Million	-1.18%
2017-12-31	€9.41 Million ≈ $11.00 Million	-34.91%
2016-12-31	€14.46 Million ≈ $16.90 Million	+11.98%
2015-12-31	€12.91 Million ≈ $15.09 Million	+19.24%
2014-12-31	€10.82 Million ≈ $12.66 Million	+39.44%
2013-12-31	€7.76 Million ≈ $9.08 Million	--

About Abionyx Pharma SA

PA:ABNX France Biotechnology

Market Cap

$75.31 Million

€64.42 Million EUR

Market Cap Rank

#20405 Global

#312 in France

Share Price

€1.83

Change (1 day)

-4.20%

52-Week Range

€1.67 - €5.00

All Time High

€12.79